Tettero, Jesse M; Ngai, Lok Lam; Bachas, Costa; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Gradowska, Patrycja; Griskevicius, Laimonas; Janssen, Jeroen J W M; Juliusson, Gunnar; Maertens, Johan; Manz, Markus G; Pabst, Thomas; Passweg, Jakob; Porkka, Kimmo; Valk, Peter J M; Löwenberg, Bob; Ossenkoppele, Gert J; Cloos, Jacqueline (2023). Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. Haematologica - the hematology journal, 108(10), pp. 2794-2798. Ferrata-Storti Foundation 10.3324/haematol.2022.282639
|
Text
11047-Article_Text-80846-1-10-20230406.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (2MB) | Preview |
Not available.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Pabst, Thomas Niklaus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0390-6078 |
Publisher: |
Ferrata-Storti Foundation |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
11 Apr 2023 14:02 |
Last Modified: |
20 Jun 2024 08:56 |
Publisher DOI: |
10.3324/haematol.2022.282639 |
PubMed ID: |
37021540 |
BORIS DOI: |
10.48350/181594 |
URI: |
https://boris.unibe.ch/id/eprint/181594 |
Actions (login required)
 |
Edit item |